Thrombocytopenia

Etiology and Risk Factors

Causes fall into three mechanisms (Davoren & Hsu, 2019; Norris, 2020):

• Decreased production: Aplastic anemia, marrow replacement by leukemia or metastatic tumor, chemotherapy and radiation, viral suppression of megakaryocytes by HIV or cytomegalovirus, and reduced thrombopoietin production in cirrhosis
• Sequestration: The spleen normally holds 30% to 40% of the platelet mass and can hold up to 90% in splenomegaly
• Increased destruction or consumption: Immune thrombocytopenia (ITP), drug-induced immune thrombocytopenia, HIT, disseminated intravascular coagulation (DIC), TTP, and mechanical injury from prosthetic heart valves or malignant hypertension

Drugs associated with immune thrombocytopenia include quinine, nonsteroidal anti-inflammatory drugs (NSAIDs), penicillins and cephalosporins, sulfonamides, the glycoprotein IIb/IIIa inhibitors, and heparin (Davoren & Hsu, 2019; Norris, 2020).

Epidemiology and Clinical Context

Thrombocytopenia is a commonly encountered laboratory abnormality. Increased destruction is much more prevalent than decreased production, and immune-mediated destruction by drugs or autoantibodies is the most common mechanism (Davoren & Hsu, 2019).

Heparin is the most important drug cause because it is used so often in hospitalized patients and can trigger life-threatening thrombosis. The risk of HIT is about 10 times higher with unfractionated heparin than with low-molecular-weight heparin, higher after cardiac and orthopedic surgery (1% to 5%) than in medical or obstetric patients (0.1% to 1%), and twice as high in women (Davoren & Hsu, 2019).

Primary ITP occurs in children and adults. It is classified as newly diagnosed (up to 3 months), persistent (3 to 12 months), or chronic (more than 12 months), and secondary ITP is associated with autoimmune disease and chronic infections such as H. pylori, hepatitis C, and HIV (Norris, 2020).

Pathophysiology

Platelets are fragments of marrow megakaryocytes that circulate for about 10 days. Thrombopoietin drives their production, and because circulating platelets bind and clear thrombopoietin, a low platelet mass raises free thrombopoietin and stimulates production (Davoren & Hsu, 2019).

Immune Thrombocytopenia

Antibodies against platelet glycoproteins IIb/IIIa and Ib/IX mark platelets for destruction in the spleen and may also impair production. Abnormal T-cell regulation, including dysfunction of regulatory T cells, appears to drive the autoimmune response (Norris, 2020).

Drug-Induced Immune Thrombocytopenia

Mechanisms include antibodies that bind platelets only in the presence of the drug, as with quinine and NSAIDs; drugs acting as haptens, as with penicillins and cephalosporins; drug-induced autoantibodies that persist without the drug; and rapid immune destruction within hours of exposure to glycoprotein IIb/IIIa inhibitors (Davoren & Hsu, 2019).

Heparin-Induced Thrombocytopenia

Heparin binds platelet factor 4 (PF4), released from platelet granules, and the heparin-PF4 complex becomes an antigen. IgG antibodies against the complex bind platelets through their Fc receptors, activating and cross-linking them. Activated platelets release more PF4, perpetuating the cycle, and antibody binding to heparin-like molecules on endothelium adds vascular injury and tissue factor release. The result is platelet consumption together with a burst of thrombin generation (Davoren & Hsu, 2019). A separate, nonimmune fall in platelets early in heparin therapy is mild, transient, and clinically insignificant (Davoren & Hsu, 2019; Norris, 2020).

Thrombotic Thrombocytopenic Purpura

TTP results from deficiency of ADAMTS13, the enzyme that cleaves large von Willebrand factor multimers. Most cases are acquired. Unchecked platelet aggregation forms microthrombi in arterioles and capillaries of the brain, heart, and kidneys, and red cells are fragmented as they pass through partially occluded vessels (Norris, 2020).

Clinical Manifestations

Bleeding from thrombocytopenia is mucocutaneous. Common manifestations include (Davoren & Hsu, 2019; Norris, 2020):

• Petechiae
• Purpura in dependent areas
• Easy bruising
• Epistaxis
• Gum bleeding
• Heavy menstrual bleeding
• Gastrointestinal or bladder mucosal bleeding

Petechiae are characteristic of low platelet numbers and uncommon with platelet dysfunction alone. Intracranial hemorrhage is a rare danger with severe depletion (Norris, 2020).

The relationship between count and bleeding is not linear. Spontaneous bleeding is unlikely above 20,000/μL and remains uncommon until counts fall below about 5000/μL, provided coagulation factors and platelet function are otherwise normal. Aspirin and other hemostatic defects increase bleeding risk at any count (Davoren & Hsu, 2019).

HIT produces thrombosis rather than bleeding, usually at sites of prior vascular injury. In patients with atherosclerosis, arterial thrombosis presents as a painful, cool, pale, pulseless limb and may require emergent intervention. Venous thrombosis also occurs (Davoren & Hsu, 2019).

TTP presents abruptly with thrombocytopenia, hemolytic anemia with jaundice, renal dysfunction, fever, and neurologic changes ranging from headache to seizures and altered consciousness (Norris, 2020).

Diagnostic Evaluation

Confirming the Count

Review the peripheral smear to confirm a true low count. Large platelets suggest increased marrow production in response to peripheral destruction, and fragmented red cells suggest a microangiopathic process such as TTP or DIC (Davoren & Hsu, 2019).

History

Assess:

• Heparin exposure, including flushes and low-molecular-weight heparin
• New medications, including over-the-counter drugs
• Timing of the platelet fall relative to drug exposure
• Bleeding pattern and severity
• New thrombosis or limb ischemia
• Recent viral illness, HIV or hepatitis C risk
• Alcohol use or liver disease
• Autoimmune disease
• Pregnancy
• Fever, neurologic symptoms, or reduced urine output

Timing Patterns

• Drug-induced immune thrombocytopenia: Usually at least 5 to 7 days after first exposure, or within 2 to 3 days of reexposure, with recovery within days of stopping the drug (Davoren & Hsu, 2019; Norris, 2020).
• HIT: Typically 5 to 10 days after heparin exposure (Davoren & Hsu, 2019).
• Glycoprotein IIb/IIIa inhibitors: Within hours of exposure (Davoren & Hsu, 2019).

Heparin-Induced Thrombocytopenia

HIT should be suspected when the platelet count falls by more than 50% from baseline or to below 150,000/μL during heparin therapy, or when new thrombosis develops despite heparin. Platelet counts are monitored at baseline and every 2 to 3 days during unfractionated heparin therapy. Heparin is discontinued as soon as HIT is suspected (Huynh et al., 2026).

Additional Testing

Depending on the presentation, evaluation may include:

• Coagulation studies and fibrinogen when DIC is possible
• Hemolysis markers, including lactate dehydrogenase and bilirubin, when fragmented red cells are present
• Renal function
• HIV and hepatitis C testing
• Liver function and assessment for splenomegaly
• Bone marrow examination when other cytopenias or abnormal cells suggest a production problem

ITP is a diagnosis of exclusion. Platelet antibody tests lack specificity, and secondary and drug-related causes must be excluded (Norris, 2020).

Expected Findings

Findings that support each cause include (Davoren & Hsu, 2019; Huynh et al., 2026; Norris, 2020):

• ITP: Isolated thrombocytopenia, large platelets, normal red and white cells, and mucocutaneous bleeding
• Drug-induced immune thrombocytopenia: Platelet fall after a new drug with recovery after discontinuation
• HIT: Platelet fall of more than 50% or new thrombosis during heparin therapy
• TTP: Thrombocytopenia with fragmented red cells, hemolysis, renal dysfunction, and neurologic changes
• Production failure: Thrombocytopenia with additional cytopenias or abnormal cells

Differential Diagnosis

Disseminated Intravascular Coagulation

DIC consumes platelets and clotting factors together, so thrombocytopenia is accompanied by a prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), low fibrinogen, and elevated fibrin degradation products in a patient with a serious underlying illness (Davoren & Hsu, 2019; Norris, 2020). See Disseminated Intravascular Coagulation.

Hypersplenism

Splenomegaly from liver disease or other causes sequesters platelets, and splenectomy may be considered when necessary (Norris, 2020).

Marrow Failure or Infiltration

Aplastic anemia, leukemia, and metastatic tumor usually produce additional cytopenias and may show abnormal cells on the smear (Norris, 2020).

Impaired Platelet Function

Uremia, aspirin, NSAIDs, and von Willebrand disease impair platelet function, so bleeding occurs with a normal platelet count (Davoren & Hsu, 2019; Norris, 2020).

Findings That Reduce Diagnostic Probability

Few findings exclude a cause of thrombocytopenia by themselves. The following findings should redirect the evaluation:

• Anemia, neutropenia, or abnormal cells make isolated ITP less likely and point toward marrow disease (Norris, 2020).
• A platelet fall that began before heparin exposure, or a count that does not recover after heparin is stopped, makes HIT less likely (Davoren & Hsu, 2019).
• Prolonged PT and aPTT with low fibrinogen favor DIC over ITP or drug-induced thrombocytopenia (Davoren & Hsu, 2019; Norris, 2020).
• Bleeding with a normal platelet count suggests impaired platelet function or a coagulation factor deficiency (Norris, 2020).

Treatment and Management

Immune Thrombocytopenia

Treatment is based on the platelet count and bleeding, and many patients do well without treatment. Corticosteroids are the usual initial therapy. Intravenous immunoglobulin raises the count quickly, but the effect lasts only about 1 to 2 weeks (Norris, 2020).

Drug-Induced Immune Thrombocytopenia

Stop the suspected drug. Platelet counts usually recover within days, and rechallenge almost always reproduces the thrombocytopenia (Davoren & Hsu, 2019).

Heparin-Induced Thrombocytopenia

Management includes (Davoren & Hsu, 2019; Huynh et al., 2026):

• Stop all heparin immediately, including low-molecular-weight heparin and heparin flushes.
• Start a non-heparin anticoagulant to prevent and treat thrombosis.
• Parenteral direct thrombin inhibitors, such as argatroban, are the drugs of choice.
• Do not use low-molecular-weight heparin as the alternative because it cross-reacts with HIT antibodies.
• Some centers use fondaparinux in selected patients (Davoren & Hsu, 2019; Huynh et al., 2026).

Thrombotic Thrombocytopenic Purpura

Emergency plasmapheresis with replacement by fresh frozen plasma supplies the deficient enzyme. With treatment, complete recovery occurs in about 80% of cases (Norris, 2020).

Complications and Red Flags

Urgent escalation is required for:

• Platelet fall of more than 50% during heparin therapy
• New arterial or venous thrombosis with a falling platelet count
• A cool, pale, pulseless limb
• Thrombocytopenia with fragmented red cells, neurologic change, fever, or renal dysfunction
• Severe thrombocytopenia with active bleeding
• Headache or neurologic change with severe thrombocytopenia
• Thrombocytopenia with other cytopenias or blasts

Clinical Reasoning Priorities

Use the CBC and smear to separate isolated peripheral destruction from marrow disease. Thrombosis or a platelet fall of more than 50% during heparin exposure should immediately raise concern for HIT (Davoren & Hsu, 2019; Huynh et al., 2026; Norris, 2020).

---

---

References

Davoren, J. B., & Hsu, G. (2019). Blood disorders. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed.). McGraw-Hill Education.

Huynh, N. S., Cantrell, M., & Lee, J. C. (2026). Venous thromboembolism. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.

Norris, T. L. (2020). Porth’s essentials of pathophysiology (5th ed.). Wolters Kluwer.